Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04194008 · ClinicalTrials.gov registry record · NA

Efficacy and Safety of Nerivio Device for Acute Treatment of Migraine in People With Chronic Migraine

A NA study, sponsored by Theranica.

Completed
Registry status
NA
Development phase
126
Enrollment target

NCT04194008 is a NA study that has completed, run by Theranica. The registered enrollment target is 126 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04194008, a NA study, has completed, sponsored by Theranica.

COMPLETED
Registry status
NA
Development phase
126 participants
Enrollment target

Study Summary

A prospective, single arm, open-label, multicenter trial to assess the efficacy and safety of the Nerivio device in chronic migraine patients. This study will be conducted in three phases: Phase I - Run-in: Eligible participants will be trained to use a smartphone migraine diary application. During the 4 weeks of this phase, participants will be instructed to report all their migraines and headaches at onset, 2 hours and 24 hours post report . Phase II - Treatment: A 4-week treatment phase in which participants will be asked to treat their migraine headaches with the Nerivio device and report it using the smartphone application at baseline, 2 hours and 24 hours post-treatment. Phase III - Follow-up: An 8-week follow-up phase in which participants will incorporate the Nerivio device into their usual care according to their preference (Nerivio only, medication only, both or none). Participants will be asked to report all their migraines or headaches at onset, 2 hours post report and 24 hours post report.

Interventions

  • DEVICE Nerivio

Trial Details

FieldValue
Enrollment Target 126 participants
Start Date 2019-11-18
Est. Completion 2020-08-30
Phase NA

Sponsor

Theranica

22 total trials

What the Registry Record Tells You About NCT04194008

The ClinicalTrials.gov registry entry for NCT04194008 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Theranica, which has 22 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Nerivio is the first listed.

NCT04194008 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04194008 about?

NCT04194008 is a clinical study titled "Efficacy and Safety of Nerivio Device for Acute Treatment of Migraine in People With Chronic Migraine". A prospective, single arm, open-label, multicenter trial to assess the efficacy and safety of the Nerivio device in chronic migraine patients. This study will be conducted in three phases: Phase I - Run-in: Eligible participants will be trained to use a smartphone migraine diary application. Durin...

What is the current status of trial NCT04194008?

This trial is currently completed. It is a NA study. The enrollment target is 126 participants. The study started on 2019-11-18. Estimated completion is 2020-08-30.

What interventions are being tested in trial NCT04194008?

The interventions under investigation include: Nerivio (DEVICE).

Who is sponsoring clinical trial NCT04194008?

This trial is sponsored by Theranica, which has 22 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.